Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats

Psychopharmacology

Volumn 170, Issue 4, 2003, Pages 335-342

  Bertoglio, Leandro J ^a   Carobrez, Antonio P ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Anxiety; Elevated plus maze; Glycine B antagonist; NMDA antagonist; One trial tolerance

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 4 AMINOBUTYRIC ACID A RECEPTOR; DIZOCILPINE; GLYCINE B RECEPTOR; GLYCINE RECEPTOR; LIGAND; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERANCE; ELEVATED PLUS MAZE TEST; EXPLORATORY BEHAVIOR; MALE; MAZE TEST; NONHUMAN; ONE TRIAL TOLERANCE; PHENOMENOLOGY; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MAZE LEARNING; MEMANTINE; PYRROLIDINONES; RATS; RATS, WISTAR; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0347604922     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1558-z     Document Type: Article

References (47)

1. Bertoglio LJ, Carobrez AP (2000) Previous maze experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. Behav Brain Res 108:197-203
2. Bertoglio LJ, Carobrez AP (2002a) Anxiolytic effects of ethanol and phenobarbital are abolished in test-experienced rats submitted to the elevated plus maze. Pharmacol Biochem Behav 73:963-969
3. Bertoglio LJ, Carobrez AP (2002b) Behavioral profile of rats submitted to session 1-session 2 in the elevated plus-maze during diurnal/nocturnal phases and under different illumination conditions. Behav Brain Res 132:135-143
4. Bertoglio LJ, Carobrez AP (2002c) Prior maze experience required to alter midazolam effects in rats submitted to the elevated plus-maze. Pharmacol Biochem Behav 72:449-455
5. A receptors by protein phosphorylation. In: Martin PI, Olsen RW (eds) GABA in the nervous system. Lippincott Williams & Wilkins, Philadelphia, pp 191-206
6. Canto-de-Souza A, Nunes-de-Souza RL, Rodgers RJ (2002) Anxiolytic-like effect of WAY-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience. Brain Res 928:50-59
7. Carobrez AP, Teixeira KV, Graeff FG (2001) Modulation of defensive behavior by periaqueductal gray NMDA/glycine-B receptor. Neurosci Bio Behav Rev 25:697-709
8. Chacur C, Raymond R, Hipolide DC, Giugliano EB, Leite JR, Nobrega JN (1999) Immediate increase in benzodiazepine binding in rat brain after a single brief experience in the plus maze: a paradoxical effect. Neurosci Lett 269:29-32
9. Chandler LJ, Harris RA, Crews FT (1998) Ethanol tolerance and synaptic plasticity. Trends Pharmacol Sci 19:491-495
10. Corbett R, Dunn RW (1991) Effects of HA-966 on conflict, social interaction, and plus maze behaviors. Drug Dev Res 24:201-205
11. Criswell HE, Breese GR (1989) A conflict procedure not requiring deprivation: evidence that chronic ethanol treatment induces tolerance to the anticonflict action of ethanol and chlordiazepoxide. Alcohol Clin Exp Res 13:680-685
12. Criswell HE, Overstreet DH, Rezvani AH, Johnson KB, Simson PE, Knapp DJ, Moy SS, Breese GR (1994) Effects of ethanol, MK-801, and chlordiazepoxide on locomotor activity in different rat lines: dissociation of locomotor stimulation from ethanol preference. Alcohol Clin Exp Res 18:917-923
13. Cruz-Morales SE, Santos NR, Brandão ML (2002) One-trial tolerance to midazolam is due to enhancement of fear and reduction of anxiolytic- sensitive behaviors in the elevated plus-maze retest in the rat. Pharmacol Biochem Behav 72:973-978
14. Dal-Cól MLC, Orlandi-Pereira L, Rosa VP, Calixto AV, Carobrez AP, Faria MS (2003) Lack of midazolam-induced anxiolysis in the plus-maze trial 2 is dependent on the length of trial 1. Pharmacol Biochem Behav 74:395-400
15. Dawson GR, Crawford SP, Stanhope KJ, Iversen SD, Tricklebank MD (1994) One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure. Psychopharmacology 113:570-572
16. Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7-61
17. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 169:1-10
18. Dunn RW, Flanagan DM, Martin LL, Kerman LL, Woods AT, Camacho F, Wilmot CA, Cornfeldt ML, Effland RC, Wood PL et al. (1992) Stereoselective R-(+) enantiomer of HA-966 displays anxiolytic effects in rodents. Eur J Pharmacol 22:207-214
19. Fernandes C, File SE (1996) The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav 54:31-40
20. File SE (1993) The interplay of learning and anxiety in the elevated plus-maze. Behav Brain Res 58:199-202
21. File SE, Zangrossi HJr (1993) "One-trial tolerance" to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology 110:240-244
22. File SE, Mabbutt PS, Hitchcott PK (1990) Characterisation of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology 102:98-101
23. File SE, Zangrossi HJr, Viana M, Graeff FG (1993) Trial 2 in the elevated plus-maze: a different form of fear? Psychopharmacology 111:491-494
24. Frussa-Filho R, Ribeiro R de A (2002) One-trial tolerance to the effects of chlordiazepoxide in the elevated plus-maze is not due to acquisition of a phobic avoidance of open arms during initial exposure. Life Sci 71:519-525
25. Fujita M, Woods SW, Verhoeff NPLG, Abi-Dargham A, Baldwin RM, Zoghbi SS, Soares JC, Jatlow PA, Krystal JH, Rajeevan N, Charney DS, Seibyl JP, Innis RB (1999) Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol 368:161-172
26. Gonzalez LE, File SE (1997) A five-minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus. J Neurosci 17:1505-1511
27. Gray AJ, McNaughton N (2000) The neuropsychology of anxiety, 2nd edn. Oxford University Press, New York, pp 72-82
28. Greenamyre JT, Porter RHP (1994) Anatomy and physiology of glutamate in the CNS. Neurology 44:S7-S13
29. Guimaraes FS, Carobrez AP, De Aguiar JC, Graeff FG (1991) Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology 103:91-94
30. Handley SL, McBlane JW (1993) An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Meth 29:129-138
31. Hascoet M, Bourin M, Couetoux du Tertre A (1997) Influence of prior experience on mice behavior using the four-plate test. Pharmacol Biochem Behav 58:1131-1138
32. Hlinak Z, Krejci I (2000) Oxiracetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice. Behav Brain Res 117:147-151
33. Holmes A, Rodgers RJ (1998) Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state? Pharmacol Biochem Behav 60:473-488
34. Holmes A, Iles JP, Mayell SJ, Rodgers RJ (2001) Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test. Behav Brain Res 122:159-167
35. Itoh J, Nabeshima T, Kameyama T (1991) Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol 194:71-76
36. Jardim MC, Guimaraes FS (2001) GABAergic and glutamatergic modulation of exploratory behavior in the dorsomedial hypothalamus. Pharmacol Biochem Behav 69:579-584
37. Karcz-Kubicha M, Jessa M, Nazar M, Plaznik A, Hartmann S, Parsons CG, Danysz W (1997) Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology 36:1355-1367
38. Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDA-receptor expressed in Xenopus oocyte. Science 241:835-837
39. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185
40. McGregor IS, Dielenberg RA (1999) Differential anxiolytic efficacy of a benzodiazepine on first versus second exposure to a predatory odor in rats. Psychopharmacology 147:174-181
41. Nunes-de-Souza RL, Canto-de-Souza A, Rodgers RJ (2002) Effects of intra-hippocampal infusion of WAY-100635 on plus-maze behavior in mice. Influence of site of injection and prior test experience. Brain Res 927:87-96
42. Ottersen OP, Storm-Mathisen J (eds) (2000) Glutamate. Elsevier, New York, pp 63-110
43. Pereira JK, Vieira RJ, Konishi CT, Ribeiro RA, Frussa-Filho R (1999) The phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze is abolished by the introduction of a motivational conflict situation. Life Sci 65:101-107
44. Rodgers RJ, Shepherd JK (1993) Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 113:237-242
45. Tabakoff B, Hoffman PL (1992) Alcohol: neurobiology. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds) Substance abuse a comprehensive textbook, 2nd edn. Williams & Wilkins, Baltimore, pp 152-185
46. Teixeira KV, Carobrez AP (1999) Effects of glycine or (±)-3-amino-1-hydroxy-2-pyrrolidone microinjections along the rostrocaudal axis of the dorsal periaqueductal gray matter on rats' performance in the elevated plus-maze task. Behav Neurosci 113:196-203
47. Tingley WG, Roche KW, Thompson AK, Huganir RL (1993) Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. Nature 364:70-73